MindMaze Taps Zach Henderson as CEO to Drive Global Commercial Expansion

The appointment of Zach Henderson as Chief Executive Officer of MindMaze Therapeutics marks a definitive turning point for the Swiss-born digital health unicorn. For years, MindMaze has been recognized as a pioneer in the neurotherapeutics space, blending virtual reality (VR), motion capture, and artificial intelligence to treat neurological conditions such as stroke, Parkinson’s disease, and multiple sclerosis. However, the transition from a founder-led R&D powerhouse to a commercially dominant global entity requires a specific pedigree of leadership—one that Henderson is expected to provide.

Henderson enters the role at a critical juncture for the digital therapeutics (DTx) industry. The sector has faced significant headwinds over the last 24 months, characterized by high-profile bankruptcies and a tightening venture capital environment that now prioritizes path-to-profitability over pure innovation. By bringing in a 'HealthTech Veteran,' MindMaze is signaling to its investors and the broader market that it is ready to move beyond the pilot phase and into the standard-of-care phase. Henderson’s primary mandate will be to navigate the complex reimbursement landscapes of the United States and Europe, where digital interventions often struggle to find consistent coding and payment pathways despite strong clinical evidence.

“

The appointment of Zach Henderson as Chief Executive Officer of MindMaze Therapeutics marks a definitive turning point for the Swiss-born digital health unicorn.

MindMaze’s core technology, which includes the MindMotion and MindPod platforms, relies on the principle of neuroplasticity—the brain's ability to reorganize itself by forming new neural connections. While the clinical efficacy of these tools has been well-documented in peer-reviewed journals, the commercial challenge lies in integration. Henderson will likely focus on deep-tier partnerships with hospital networks and rehabilitation centers, moving the technology from a 'novelty' add-on to a core component of the neurological recovery workflow. This involves not just selling hardware and software, but managing the data-driven insights that allow clinicians to track patient progress in real-time.